Isconova’s adjuvant technology can be use for a wide variety of applications at different stages of research, product development and manufacturing.

Immunology research

Examples of successful ISCOM technology-based vaccine formulations abound in the literature. To date, over 450 publications describe their immunopotentiating properties in terms of antibody responses, cellular responses, cytokine and chemokine production, and protection against infection. (See Publications & Reviews) Commercially, several animal vaccines are already registered.

A better means of vaccine development

Part of our core competence is to act as the given partner for vaccine developing companies and government institutions who want to develop successful and innovative vaccines and bring them to market. Isconova has greatly improved the ISCOM technology, resulting in a patented, new-generation state-of-the-art form that displays superior safety and performance. Isconova’s adjuvants are thus safe, efficient and, most important of all, well proven and documented.

Antibody production

ISCOM technology is well-recognised for inducing strong activation of both the cell-mediated (Th1 response) and the humoral (Th2 response) arms of the immune system. This key property gives rise to a strong immune response with a broad range and a higher concentration of antibody variants.